Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | The following directors and officers adopted into or terminated a Rule 10b5-1 trading arrangement during the first quarter of 2026: • Edward M. Kaye, M.D. – Dr. Kaye, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement on March 2, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Kaye Plan”). The Kaye Plan provides for the sale of up to 29,347 shares of our common stock, subject to certain conditions. The Kaye Plan will terminate on the of (x) February 28, 2027 and (y) the sale of all securities that are subject to the plan. Certain of our officers have made elections to participate in, and are participating in, our employee stock purchase plan, which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements. In addition, certain of our directors have made elections to participate in, and are participating in, our director equity in lieu of cash retainer option program (as described in the “Director Compensation” section of our Proxy Statement for our 2024 Annual Meeting), which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements. |
| Edward M. Kaye [Member] | |
| Trading Arrangements, by Individual | |
| Name | Edward M. Kaye |
| Title | M.D |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 2, 2026 |
| Rule 10b5-1 Arrangement Terminated | false |
| Expiration Date | February 28, 2027 |
| Arrangement Duration | 364 days |
| Aggregate Available | 29,347 |